The infrastructure for quality and compliance control is crucial for companies to keep pace with the demands of today’s modern pharmaceutical manufacturing. To meet these demands, DSM is on a path of critical modernization, making continuous and considerable investments in global validated solutions for multiple IT systems.
We spoke with three DSM experts to gain valuable insight on the impact of the company’s investments, now and in the future, along with the potential risks and the benefits for sustainability, customers and ultimately – patients. Read on to hear from Rob Everink (Digital Implementation Officer OT –Operations), Srini Putluri (Global Quality Manager - IT Systems – Operations) and Fraser Strachan (Senior Global Quality Manager GMP compliance - Operations).
DSM has committed to multiple investment programs which enable the company to stay on the pulse of innovation while conducting due diligence to the best of its capabilities. Perhaps the most significant and widely used systems in our manufacturing network are Global Laboratory Information Management System (LIMS), Global Chromatography Data System (CDS) and a validated Data Historian for Production System data. DSM’s rollout of substantial IT solutions supports a products manufacturing lifecycle, from start-to-end, and assures the highest standards in the industry.
Srini Putluri, Global Quality Manager - IT Systems – Operations, remarks on how these IT upgrades will benefit patients: “Increasing the digitalization of our manufacturing lifecycle processes is critically important to assure our IT systems are operating at optimal efficiency and quality. These improvements will yield products that are as safe and effective as possible, ultimately benefiting the end user – patients.”
DSM’s strategy to advance the rollout of global validated solutions for multiple systems is the best approach to mitigate risks. Our investments enhance data integrity, quality and compliance, while also minimizing the risk of human error. Although there are significant costs associated with setting up these systems, once they are implemented, they will minimize errors, improve quality and streamline manufacturing – resulting in reduced costs.
Digitalization is the future of pharma, and DSM’s investments in IT and automation are preparing the company for the next steps ahead. While it may take some time for everyone to become fully confident with this new way of working, in the future we can expect improved system reports. These reports will facilitate a focus on process deviation and not the parts of production that are running efficiently – meaning less time will be required to check the production and quality control data. Ultimately, these systems will improve both our efficiency and quality of production.
Fraser Strachan, Senior Global Quality Manager GMP compliance – Operations remarks: “DSM’s investments will maximize the impact and ease the roll out of future system upgrades, improving engagement with our end users. Our customers can be confident in a partnership with DSM as our IT investments demonstrate that we are committed to prioritizing their compliance needs, both now and in the long-term.”
We're uniquely powered to deliver more than active pharmaceutical ingredients. Our end-to-end capabilities can help companies create purposeful and safe therapeutics that improve patient's quality of life. Not only do we offer high-quality ingredients, customized solutions and technical expertise, but our investments in the future of pharma keep us on the pulse of innovation in this space.
Want to know more about how DSM can help you succeed in the pharma market? Get in touch here to explore our pharmaceutical products.
04 May 2023
4 min read